Hemopressin Peptides: A New Class of Endogenous Cannabinoid Modulators With Therapeutic Potential
A review of hemopressin peptides, naturally occurring molecules that modulate cannabinoid receptors, highlights their potential for pain relief, appetite suppression, and blood pressure regulation.
Quick Facts
What This Study Found
Hemopressin is a naturally occurring brain peptide derived from hemoglobin that acts as a negative allosteric modulator of CB1 cannabinoid receptors. This review examines the growing understanding of this peptide family and its therapeutic potential.
Hemopressin shows pain-relieving (antinociceptive), appetite-suppressing (hypophagic), and blood-pressure-lowering (hypotensive) effects. However, there is debate about whether hemopressin itself is the active endogenous molecule or a degradation product of a longer peptide, RVD-hemopressin, which may be more biologically active.
RVD-hemopressin appears to bind to a similar site as rimonabant on the CB1 receptor and may also interact with opioid receptors. This dual-receptor activity opens possibilities for developing cannabinoid peptide drugs that simultaneously affect both pain systems.
Key Numbers
Hemopressin: nonapeptide from hemoglobin alpha-chain. RVD-hemopressin: longer, possibly more active precursor. Effects include antinociception, hypophagia, and hypotension. May share binding site with rimonabant. Possible cross-reactivity with opioid receptors.
How They Did This
Narrative review of preclinical evidence on hemopressin, its peptide derivatives, and synthetic analogs, covering their pharmacology, physiological effects, and potential therapeutic applications.
Why This Research Matters
The discovery of endogenous peptides that modulate cannabinoid receptors adds a new dimension to the endocannabinoid system. Unlike lipid endocannabinoids, peptides can be more easily modified by medicinal chemistry to create drugs with specific properties.
The Bigger Picture
Cannabinoid peptides represent a relatively new discovery that could expand the therapeutic toolkit. Their natural ability to modulate cannabinoid receptors, combined with the ease of peptide chemistry, makes them attractive starting points for developing drugs that could treat pain, obesity, and hypertension.
What This Study Doesn't Tell Us
The endogenous status of hemopressin versus RVD-hemopressin is still debated. Most evidence is from animal studies. Peptide drugs face challenges with stability, bioavailability, and brain penetration. The precise binding mechanisms remain to be fully characterized.
Questions This Raises
- ?Is hemopressin or RVD-hemopressin the true endogenous modulator?
- ?Could synthetic hemopressin analogs be developed into clinically useful drugs?
- ?How do cannabinoid peptides interact with the classical endocannabinoid system?
Trust & Context
- Key Stat:
- Hemopressin peptides: a new class of endogenous cannabinoid modulators
- Evidence Grade:
- Narrative review of an emerging research area with primarily preclinical evidence and unresolved fundamental questions.
- Study Age:
- Published in 2016. Hemopressin research continues but remains in early preclinical stages.
- Original Title:
- Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.
- Published In:
- Protein and peptide letters, 23(12), 1045-1051 (2016)
- Authors:
- Macedonio, Giorgia(3), Stefanucci, Azzurra(3), Maccallini, Cristina, Mirzaie, Sako, Novellino, Ettore, Mollica, Adriano
- Database ID:
- RTHC-01220
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are cannabinoid peptides?
They are naturally occurring molecules in the brain, derived from hemoglobin, that can modulate cannabinoid receptors. They represent a new type of endogenous cannabinoid system component distinct from the classical lipid endocannabinoids.
Could these peptides become medicines?
Potentially. Their effects on pain, appetite, and blood pressure are therapeutically relevant, and their peptide nature makes them amenable to chemical modification for drug development, though significant research remains.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01220APA
Macedonio, Giorgia; Stefanucci, Azzurra; Maccallini, Cristina; Mirzaie, Sako; Novellino, Ettore; Mollica, Adriano. (2016). Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.. Protein and peptide letters, 23(12), 1045-1051.
MLA
Macedonio, Giorgia, et al. "Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools.." Protein and peptide letters, 2016.
RethinkTHC
RethinkTHC Research Database. "Hemopressin Peptides as Modulators of the Endocannabinoid Sy..." RTHC-01220. Retrieved from https://rethinkthc.com/research/macedonio-2016-hemopressin-peptides-as-modulators
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.